Biotechnology Assets [BST] vs Oryzon Genomics S.A [ORY] Detailed Stock Comparison

Biotechnology Assets S.A.

BME
Loading...

Oryzon Genomics S.A.

BME
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Biotechnology Assets S.A. wins in 4 metrics, Oryzon Genomics S.A. wins in 10 metrics, with 1 ties. Oryzon Genomics S.A. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Biotechnology Assets S.A. Oryzon Genomics S.A. Better
P/E Ratio (TTM) 10.77 N/A N/A
Price-to-Book Ratio 2.60 1.85 Oryzon Genomics S.A.
Debt-to-Equity Ratio 33.82 15.07 Oryzon Genomics S.A.
PEG Ratio N/A 55.92 N/A
EV/EBITDA -13.27 -37.27 Biotechnology Assets S.A.
Profit Margin (TTM) -68.10% -23.83% Oryzon Genomics S.A.
Operating Margin (TTM) -85.89% 53.04% Oryzon Genomics S.A.
EBITDA Margin (TTM) N/A 53.04% N/A
Return on Equity -30.40% -2.53% Oryzon Genomics S.A.
Return on Assets (TTM) -7.67% -2.81% Oryzon Genomics S.A.
Free Cash Flow (TTM) $-794,574 $-13.40M Biotechnology Assets S.A.
1-Year Return -16.13% 2.95% Oryzon Genomics S.A.
Price-to-Sales Ratio (TTM) 6.32 20.26 Biotechnology Assets S.A.
Enterprise Value $18.72M $208.60M Oryzon Genomics S.A.
EV/Revenue Ratio 6.13 19.08 Biotechnology Assets S.A.
Revenue per Share (TTM) $0 $0 Oryzon Genomics S.A.
Earnings per Share (Diluted) $-0.03 $-0.03 Tie
Beta (Stock Volatility) 1.78 0.44 Oryzon Genomics S.A.

Biotechnology Assets S.A. vs Oryzon Genomics S.A. Stock Performance Analysis

Loading Price Chart...

BST
ORY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Biotechnology Assets S.A.0.00%8.33%13.04%30.00%-27.78%30.00%
Oryzon Genomics S.A.-1.34%-3.13%0.72%-12.81%-12.81%-13.35%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Biotechnology Assets S.A.-16.13%-21.21%-70.79%-91.88%-88.50%-88.50%
Oryzon Genomics S.A.2.95%31.60%-21.41%-5.42%-21.41%-21.41%

Performance & Financial Health Analysis: Biotechnology Assets S.A. vs Oryzon Genomics S.A.

MetricBSTORY
Market Information
Market Cap i€19.30M€220.00M
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i226,591235,645
90 Day Avg. Volume i275,900275,214
Last Close€0.26€2.79
52 Week Range€0.18 - €0.49€2.51 - €4.02
% from 52W High-46.83%-30.60%
All-Time High€13.98 (Jun 23, 2014)€5.25 (Dec 14, 2015)
% from All-Time High-98.14%-46.86%
Growth Metrics
Quarterly Revenue Growth0.08%0.49%
Quarterly Earnings GrowthN/AN/A
Financial Health
Profit Margin (TTM) i-0.68%-0.24%
Operating Margin (TTM) i-0.86%0.53%
Return on Equity (TTM) i-0.30%-0.03%
Debt to Equity (MRQ) i33.8215.07
Cash & Liquidity
Book Value per Share (MRQ)€0.10€1.52
Cash per Share (MRQ)€0.01€0.37
Operating Cash Flow (TTM) i€574,211€-2,356,163
Levered Free Cash Flow (TTM) i€-329,133€-11,863,420
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Biotechnology Assets S.A. vs Oryzon Genomics S.A.

MetricBST (Apr 26, 2026)ORY (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i10.77N/A
Forward P/E iN/A55.92
PEG Ratio iN/A55.92
Price to Sales (TTM) i6.3220.26
Price to Book (MRQ) i2.601.85
Market Capitalization
Market Capitalization i€19.30M€220.00M
Enterprise Value i€18.72M€208.60M
Enterprise Value Metrics
Enterprise to Revenue i6.1319.08
Enterprise to EBITDA i-13.27-37.27
Risk & Other Metrics
Beta i1.780.44
Book Value per Share (MRQ) i€0.10€1.52

Financial Statements Comparison: Biotechnology Assets S.A. vs Oryzon Genomics S.A.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBST (2024)ORY (2025)
Revenue/Sales i2.51M0
Cost of Goods Sold i-138,410-10.65M
COGS % of Revenue i-5.5%-
Gross Profit i2.65M10.65M
Gross Margin i105.5%-
Research & Development i0N/A
Operating Income (EBIT) i-2.22M-5.71M
Operating Margin i-88.1%-
EBITDA i-110,145-4.81M
EBITDA Margin i-4.4%-
Pre-Tax Income i-3.06M-5.60M
Pre-Tax Income % of Revenue i-121.5%-
Income Tax i-139,119-2.99M
Income Tax % of Revenue i-5.5%-
Net Income (Profit) i-2.92M-2.61M
Profit Margin i-116.0%-

Balance Sheet & Liquidity Metrics

MetricBST (2024)ORY (2025)
Cash & Equivalents i143,82228.35M
Total Current Assets i3.70M30.67M
Total Current Assets % of Revenue i147.1%-
Total Current Liabilities i4.55M15.77M
Total Current Liabilities % of Revenue i180.9%-
Long-Term Debt i2.39M3.08M
Long-Term Debt % of Revenue i95.0%-
Total Shareholders Equity i6.61M117.85M
Retained Earnings i-23.57M-20.81M
Retained Earnings % of Revenue i-937.2%-
Property, Plant & Equipment i481,1991.16M

Cash Flow Statement Comparison

MetricBST (2024)ORY (2025)
Operating Cash Flow i-3.00M-6.19M
Operating Cash Flow % of Revenue i-119.3%-
Capital Expenditures i-13,765-59,394
Free Cash Flow i-794,574-13.40M
FCF Margin i-31.6%-
Debt Repayment i-1.65M-11.37M
Common Stock Repurchase i-120,5250

Short Interest & Institutional Ownership Analysis

MetricBSTORY
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i68.09M77.51M
Float Shares iN/A60.52M
% Held by Insiders i45.27%21.27%
% Held by Institutions i0.10%0.75%
% Held by Public i54.63%77.98%

Dividend Analysis & Yield Comparison: Biotechnology Assets S.A. vs Oryzon Genomics S.A.

MetricBSTORY
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A